Lamictal Case Won't Be Paused For Class Cert. Appeal
Law360 (February 15, 2019, 6:21 PM EST) -- A New Jersey federal judge on Friday refused to pause a case accusing GlaxoSmithKline PLC and Teva Pharmaceutical Industries Ltd. of delaying the entry of generic alternatives to epilepsy drug Lamictal while the drugmakers try to appeal a class certification ruling to the Third Circuit.
U.S. Magistrate Judge Cathy L. Waldor issued a text order Friday staying the sending of class notices at least until the circuit court decides on the companies' petition for an immediate appeal of the ruling. But the order also denied GSK and Teva's January request to put the district court proceedings on hold in their entirety while the...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!